Teleflex (TFX)
NYSE:TFX
Want to see TFX full AI Analyst Report?
Top Page
Teleflex
(NYSE:TFX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$137.00
▲(4.12% Upside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by weak financial performance (large recent losses and revenue contraction) and poor valuation optics (negative P/E). These are partially offset by solid cash flow/leverage improvement, constructive technical momentum, and reaffirmed guidance alongside a post-separation margin recovery plan—though near-term margin, remediation, and execution/timing risks remain notable.
Positive Factors
Recurring consumable device portfolio
Teleflex’s core products are single-use consumables sold to hospitals and clinicians, creating high repeat purchase frequency tied to procedure volumes. This business model produces recurring revenue, predictable demand across cycles, and durable installed-base economics that support steady cash generation and market share retention.
Negative Factors
Severe profitability deterioration
A deep net loss and negative EBITDA signal impaired earnings quality and weakened return metrics. Sustained losses erode equity, constrain reinvestment and limit capacity to absorb shocks. Even if some items are non‑cash, persistent bottom‑line weakness threatens long‑term ROE and restricts strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable device portfolio
Teleflex’s core products are single-use consumables sold to hospitals and clinicians, creating high repeat purchase frequency tied to procedure volumes. This business model produces recurring revenue, predictable demand across cycles, and durable installed-base economics that support steady cash generation and market share retention.
Read all positive factors
Teleflex Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyTeleflex (TFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.88B
Dividend Yield1.11%
Average Volume (3M)932.60K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth-6.61%
EPS Growth-812.37%
CountryUS
Employees14,100
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-22.80
Shares Outstanding44,270,210
10 Day Avg. Volume689,029
30 Day Avg. Volume932,595
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit3.83
Enterprise Value/Ebitda-64.87
Forecast
1Y Price Target
$145.38Price Target Upside10.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)6.7
Revenue Forecast (FY)$2.29B
Teleflex Business Overview & Revenue Model
Company Description
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that compris...
How the Company Makes Money
Teleflex primarily makes money by selling disposable and single-use medical devices and related consumables to hospitals and healthcare providers. Revenue is generated from product sales across its major therapy and procedure areas (e.g., vascular...
Teleflex Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.Positive Updates
Revenue Growth — Q1 2026
Total continuing operations revenue of $548.3 million in Q1 2026, up 32.3% year-over-year on a GAAP basis and up 5.1% on a pro forma adjusted constant currency basis.
Negative Updates
Margin Compression — Q1 2026
Adjusted gross margin declined by 470 basis points to 61.4% year-over-year and adjusted operating margin declined by 510 basis points to 18.1%, driven by tariffs, quality remediation charges, higher logistics/distribution costs and the lower-margin Vascular Intervention acquisition.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth — Q1 2026
Total continuing operations revenue of $548.3 million in Q1 2026, up 32.3% year-over-year on a GAAP basis and up 5.1% on a pro forma adjusted constant currency basis.
Read all positive updates
Company Guidance
Teleflex reiterated 2026 continuing‑operations guidance calling for pro forma adjusted constant‑currency revenue growth of 4.5%–5.5%, adjusted EPS of $6.25–$6.55, and an adjusted operating margin of ~19% (which includes roughly $90M of stranded costs and assumes R&D at ~8% of sales); management estimates an underlying steady‑state adjusted operating margin of ~23% (≈400 bps higher) once TSA/MSA benefits and stranded‑cost mitigation occur. The company expects full‑year net interest expense of ~$105M, a tax rate of ~13.5%, an FX headwind of about $14M, and assumes no 2026 benefit from TSA/MSA fees or tariff refunds in the guidance; it also reiterated plans to receive ~ $1.8B of after‑tax proceeds from the divestitures (expected to close in H2 2026, OEM in Q3), to repurchase up to $1B of stock (opportunistically beginning in Q2), to repay ~$800M of debt, noted Q1 net leverage around 2.5x, and disclosed a multiyear restructuring targeting ~ $50M of annual pretax savings by mid‑2028; guidance excludes the acute care, interventional urology and OEM businesses.Teleflex Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.81B | 1.99B | 3.05B | 2.97B | 2.79B | 2.81B |
| Gross Profit | 1.50B | 1.12B | 1.70B | 1.65B | 1.53B | 1.55B |
| EBITDA | -88.47M | 302.51M | 433.62M | 761.21M | 730.77M | 853.80M |
| Net Income | -1.01B | -905.64M | 69.67M | 356.33M | 363.14M | 485.37M |
Balance Sheet | ||||||
| Total Assets | 6.78B | 6.95B | 7.10B | 7.53B | 6.93B | 6.87B |
| Cash, Cash Equivalents and Short-Term Investments | 309.41M | 393.26M | 306.16M | 222.85M | 292.03M | 445.08M |
| Total Debt | 171.44M | 2.73B | 1.76B | 1.93B | 1.83B | 1.97B |
| Total Liabilities | 3.70B | 3.82B | 2.82B | 3.09B | 2.91B | 3.12B |
| Stockholders Equity | 3.08B | 3.12B | 4.28B | 4.44B | 4.02B | 3.75B |
Cash Flow | ||||||
| Free Cash Flow | 249.02M | 245.44M | 509.31M | 419.20M | 262.95M | 579.80M |
| Operating Cash Flow | 314.25M | 340.68M | 635.74M | 510.64M | 342.14M | 651.42M |
| Investing Cash Flow | -895.18M | -849.19M | -99.36M | -621.23M | -257.94M | 156.74M |
| Financing Cash Flow | 626.08M | 611.54M | -421.93M | 38.54M | -217.51M | -715.82M |
Teleflex Technical Analysis
Positive
131.58
Price Trends
122.63
Positive
116.44
Positive
118.99
Positive
Market Momentum
2.32
Negative
57.45
Neutral
68.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Positive. The current price of 131.58 is above the 20-day moving average (MA) of 129.18, above the 50-day MA of 122.63, and above the 200-day MA of 118.99, indicating a bullish trend. The MACD of 2.32 indicates Negative momentum. The RSI at 57.45 is Neutral, neither overbought nor oversold. The STOCH value of 68.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TFX.
Teleflex Risk Analysis
Teleflex disclosed 34 risk factors in its most recent earnings report. Teleflex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Teleflex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.23B | 39.69 | 16.19% | 0.95% | 13.27% | 36.99% | |
68 Neutral | $3.83B | 25.02 | 8.95% | ― | 11.34% | 12.26% | |
59 Neutral | $2.98B | 26.20 | 11.32% | ― | -1.97% | -38.95% | |
57 Neutral | $5.88B | -162.30 | -28.27% | 1.11% | -6.61% | -812.37% | |
57 Neutral | $3.33B | 26.54 | 2.19% | ― | -10.76% | ― | |
56 Neutral | $5.68B | -19.89 | -3.41% | ― | 7.85% | 39.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TFX
Teleflex
132.75
13.34
11.17%
HAE
Haemonetics
65.49
-0.57
-0.86%
ICUI
ICU Medical
133.31
4.32
3.35%
LMAT
Lemaitre Vascular
97.75
17.09
21.19%
MMSI
Merit Medical Systems
64.17
-31.21
-32.72%
BLCO
Bausch + Lomb Corporation
15.92
4.63
41.01%
Teleflex Corporate Events
Executive/Board ChangesShareholder Meetings
Teleflex Shareholders Endorse Directors, Pay and Auditor
Positive
May 20, 2026
Teleflex held its 2026 annual meeting of stockholders on May 15, 2026, at which shareholders voted on the election of seven directors to one-year terms, an advisory resolution on executive compensation and the ratification of PricewaterhouseCooper...
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresM&A Transactions
Teleflex Posts Q1 Results, Maintains 2026 Outlook, Plans Buyback
Neutral
May 7, 2026
Teleflex reported first-quarter 2026 results on May 7, 2026, with revenue from continuing operations rising 32.3% year over year to $548.3 million, or 5.1% on a pro forma adjusted constant currency basis, while GAAP diluted EPS from continuing ope...
Business Operations and StrategyExecutive/Board ChangesStock Buyback
Teleflex Names Jason Weidman as New CEO
Positive
Apr 30, 2026
On April 30, 2026, Teleflex announced that Medtronic veteran Jason Weidman will become President and CEO effective June 8, 2026, succeeding interim chief Stuart Randle, who remains on the board. Weidman, a 25-year medical device industry leader wi...
Business Operations and StrategyStock BuybackM&A Transactions
Teleflex Reaffirms Strategy Amid Activist Pressure on Board
Positive
Mar 27, 2026
On March 27, 2026, Teleflex reiterated its commitment to shareholder value after activist Irenic Capital urged a public strategic alternatives process and claimed the board was blocking potential acquirers. The company rejected Irenic’s char...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Teleflex Clears Key Antitrust Hurdle for OEM Divestiture
Positive
Mar 17, 2026
Teleflex reported that, on December 9, 2025, it entered into an Equity Purchase Agreement to sell its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc., an affiliate of Montagu Private Equity and Kohlberg C...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Teleflex Launches Multi-Year Restructuring to Support Divestitures
Positive
Feb 26, 2026
On February 23, 2026, Teleflex’s board approved a multi‑year restructuring tied to its planned strategic divestitures, aiming to realign its global organization and supply chain, cut stranded costs and rationalize capital assets, large...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.